ARTV
Artiva Biotherapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$279.05M
P/E Ratio
—
EPS
$-3.58
Beta
—
52W High
$14.53
52W Low
$1.47
50-Day MA
$7.38
200-Day MA
$4.54
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics, Inc. is a cutting-edge biotechnology company dedicated to advancing next-generation cell therapies for cancer treatment through its proprietary platform, which enhances natural killer (NK) cell therapies. The company boasts a robust pipeline targeting various hematologic and solid tumors, underscoring its strong commitment to innovation in the immuno-oncology space. With a focus on scientific excellence and strategic collaborations, Artiva is well-positioned to drive transformative advancements in cancer care, aiming to significantly improve patient outcomes as its promising therapeutic candidates progress through clinical development.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-87.21M |
| Operating Margin | 0.00% |
| Return on Equity | -56.60% |
| Return on Assets | -33.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.53 |
| Price-to-Book | 2.43 |
| Price-to-Sales (TTM) | 8.11 |
| EV/Revenue | 7.54 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $24.72M |
| Float | $6.00M |
| % Insiders | 27.71% |
| % Institutions | 68.86% |
Historical Volatility
HV 10-Day
147.96%
HV 20-Day
172.16%
HV 30-Day
151.51%
HV 60-Day
123.02%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($17.00 target)
1
Strong Buy5
BuyMore HEALTHCARE Stocks
Data last updated: 5/5/2026